Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Traditional Chinese Medicine Jiuwei Zhenxin Granules in Treating Depression: An Overview

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Depression is known as “Yu Zheng” in traditional Chinese medicine (TCM). Jiuwei Zhenxin granules (JZG) is a type of TCM. According to TCM theory, it nourishes the heart and spleen, tonifies Qi, and tranquilizes the spirit, and may also has effects in the treatment of depression. Here, we systematically reviewed recent basic and clinical experimental studies of JZG and depression, including studies of the pharmacological mechanisms, active ingredients, and clinical applications of JZG in depression treatment. This review will deepen our understanding of the pharmacological mechanisms, drug interactions, and clinical applications of TCM prescriptions and provide a basis for the development of new drugs in the treatment of depression.

          Related collections

          Most cited references 158

          • Record: found
          • Abstract: found
          • Article: not found

          Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.

           Anthony Grace (2016)
          The dopamine system is unique among the brain's modulatory systems in that it has discrete projections to specific brain regions involved in motor behaviour, cognition and emotion. Dopamine neurons exhibit several activity patterns - including tonic and phasic firing - that are determined by a combination of endogenous pacemaker conductances and regulation by multiple afferent systems. Emerging evidence suggests that disruptions in these regulatory systems may underlie the pathophysiology of several psychiatric disorders, including schizophrenia and depression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

            Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment. Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period. Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42). These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Mental health: a world of depression.

               Kerri Smith (2014)
                Bookmark

                Author and article information

                Journal
                Neuropsychiatr Dis Treat
                Neuropsychiatr Dis Treat
                ndt
                neurodist
                Neuropsychiatric Disease and Treatment
                Dove
                1176-6328
                1178-2021
                02 October 2020
                2020
                : 16
                : 2237-2255
                Affiliations
                [1 ]Department of Critical Care Medicine, Shengjing Hospital of China Medical University , Shenyang, Liaoning, People’s Republic of China
                Author notes
                Correspondence: Xingmao WuDepartment of Critical Care Medicine, Shengjing Hospital of China Medical University , Heping District, Shenyang, Liaoning110004, People’s Republic of China Tel/Fax +86 24 18940251899 Email cmu_xingmaowu@sina.com
                Article
                273324
                10.2147/NDT.S273324
                7541918
                © 2020 Wang and Wu.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                Page count
                Figures: 5, Tables: 6, References: 158, Pages: 19
                Funding
                There is no funding to report.
                Categories
                Review

                Neurology

                effective substance, pharmacological, yu zheng, depression, jiuwei zhenxin granules

                Comments

                Comment on this article